Omeros (OMER) Osake Kurssi

The main competitors of Omeros Corp in the market include companies such as Johnson & Johnson's Janssen Pharmaceuticals, Novartis AG, and Valeant Pharmaceuticals International Inc.

The business model of Omeros Corp is centered around developing and commercializing innovative pharmaceutical products. Omeros Corp focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, disorders of the central nervous system, and immune-related diseases. Their extensive research and development efforts aim to deliver novel treatment options to improve patient outcomes and quality of life. Omeros Corp strives to leverage their expertise in pharmacology and biology to develop transformative therapies and contribute to advancements in the healthcare industry.

Omeros Corp is a pharmaceutical company founded in 1994 and headquartered in Seattle, Washington. The company focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical indications. Omeros Corp is committed to addressing unmet medical needs and improving patients' lives. Over the years, the company has made significant advancements in the fields of ophthalmology, inflammation, and central nervous system disorders. With a strong research and development pipeline, Omeros Corp continues to strive for cutting-edge innovation and breakthrough treatments. This commitment has positioned the company as a leader in the biopharmaceutical industry, with a dedication to improving global health outcomes.

Omeros Corp, a leading biopharmaceutical company, has achieved numerous significant milestones. Since its inception, the company has made remarkable progress in the development and commercialization of innovative therapeutics. Notably, Omeros Corp has successfully launched and received approval for multiple products, such as Omidria, a widely used ophthalmic surgical drug. Furthermore, the company has also made notable advancements in its research pipeline, with promising drug candidates targeting various therapeutic areas. Omeros Corp's dedication to scientific excellence and patient care has garnered recognition and accolades within the industry. With a strong track record of achievements, Omeros Corp continues to drive innovation and improve healthcare outcomes.

Omeros Corp is primarily present in the United States.

Omeros Corp represents values of innovation, integrity, and commitment to improving global health. With a strong corporate philosophy, Omeros Corp aims to develop novel solutions for unmet medical needs and enhance patient outcomes. The company is dedicated to pioneering research and development, leveraging its expertise in pharmacology to address issues in fields like ophthalmology and pain management. Omeros Corp remains focused on driving scientific advancements, collaborating with healthcare professionals, and creating value for its patients, shareholders, and stakeholders alike. Through these principles, Omeros Corp strives to make a positive impact on the healthcare industry and the lives of individuals worldwide.

Analyytikot asettavat tällä hetkellä Omeros-osakkeelle keskimääräisen tavoitehinnan 33,00 USD (mediaani: 33,00 USD), mikä merkitsee +64,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.

Omeros Analyytikkojen kursstavoitteet 2026

10 analyytikkoa arvioi tällä hetkellä Omeros-osaketta: 7 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Omeros-yhtiöltä 127,50 M USD liikevaihtoa ja 0,83 USD osakekohtaista tulosta.

Omeros Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Omeros-osake noteerataan hintaan 17,62 EUR (20,08 USD).

Omeros-osake (OMER) on listattuna 6 pörssissä, muun muassa: NASDAQ (OMER), London (0KBU.L), SIX (Zürich) (3O8.SW), Frankfurt (3O8.F), München (3O8.MU), Düsseldorf (3O8.DU).

Omeros Corp is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic products. The company is headquartered in Seattle, Washington, with offices in Europe and Asia. Omeros Corp's business operations are determined by its three business segments: research and development, production, and marketing. Research and Development Omeros Corp's research and development segment aims to discover and develop innovative and effective therapeutics for the treatment of central nervous system, ophthalmology, and immunology diseases. The company has an extensive portfolio of products in its development pipeline, including ARTEMIS, MASP-2 inhibitors, and OMS721. ARTEMIS is an investigative product designed to enhance the efficacy of the analgesic drug Ibuprofen. The product is currently in the clinical trial phase. OMS721 is a preparation for the treatment of rare chronic kidney inflammation (IgA nephropathy) that is in the approval phase. The medication is also in Phase 3 studies for the treatment of thrombotic thrombocytopenic purpura (TTP), a disease characterized by the formation of blood clots in small blood vessels in the body. Production Omeros Corp operates a production facility in Dayton, New Jersey, specializing in the manufacture of antibiotics and generic drugs. The company also holds exclusive distribution rights for Omidria, a preparation for the prevention of pain during and after eye surgery. Omidria has been approved by the U.S. Food and Drug Administration (FDA) and is available worldwide. The medication generated revenues of $100.6 million in 2019. Marketing Omeros Corp's marketing segment is responsible for advertising, marketing, and promoting the company's products. Through a combination of traditional and digital marketing strategies, Omeros aims to bring its products to the medical community and successfully market them. The company has a dedicated team of sales representatives to ensure a strong presence in the market. Conclusion Overall, Omeros Corp has a broad portfolio of innovative medications that allows the company to potentially generate billions in revenue. The focus on researching and developing new drugs, producing existing products, and marketing Omidria has already driven growth for the company and could mean even more growth potential in the near future.

odotettu liikevaihto Omeros on 127,50 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Omeros on 52,59 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Omeros:n hinta-voitto-suhde (P/E) on tällä hetkellä 24,25. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Omeros-osakkeen arvostusta.

Omeros:n hinta-myynti-suhde (P/S) on tällä hetkellä 10,00. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Omeros-osakkeen arvostuskennuslukuna.

Omeros:n Eulpool-laatuscore on 2/10.

Omeros:n ISIN on US6821431029. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Omeros:n WKN on A0NBFF. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Omeros:n ticker on OMER. Tämä pörssinoteeraus käytetään Omeros-osakkeiden kauppaan pörssissä.

Omeros maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Omeros kuuluu sektoriin 'Terveydenhuolto'.

Omeros:n osingot jaetaan valuutassa USD.